Compare Biogen Inc (BIIB) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Prudential PLC — how do they compare? Biogen Inc trades at $207.81 (market cap $30.13B), while Prudential PLC trades at $27.53 (market cap $34.02B). The key difference: Biogen Inc and Prudential PLC are close in size by market cap, and Prudential PLC pays a 1.94% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PUK | |
|---|---|---|
Market Cap | $30.13B | $34.02B |
Sector | Health | Financials |
52-Week High | $216.63 | $33.61 |
52-Week Low | $128.93 | $24.98 |
Enterprise Value | $37.20B | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Prudential PLC (PUK) trades at $27.48, down 2.62% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income of $2.29B, while cash flow from operations surged to $3.61B. Recent news highlights a dividend declaration and strategic acquisitions, but shares face pressure from China regulatory concerns.
The outlook is mixed: attractive valuation and profitability support upside, but bearish technicals and China-related risks pose headwinds. Analyst consensus leans buy (50%), with institutional focus on execution of cost-cutting and geographic strategy. Key risks include regulatory changes in Asia and market volatility impacting near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
